Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results

      BioLife Solutions New Logo 2021 (PRNewsfoto/BioLife Solutions, Inc.)

      News provided by

      BioLife Solutions, Inc.

      Mar 16, 2023, 16:03 ET

      Share this article

      Share this article


      Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier

      Record Q4 2022 revenue of $44.3 million increased 19% over 2021; biopreservation media revenue growth of 35%

      Full year adjusted EBITDA of $3.6 million and Q4 2022 adjusted EBITDA of $1.7 million

      Conference call begins at 4:30 p.m. Eastern time today 

      BOTHELL, Wash., March 16, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.

      Mike Rice, Chairman and CEO, commented, "We closed 2022 with another year of strong performance and growth, driven by solid execution across our portfolio. Our success indicators of new customer acquisition, adoption of our cell processing solutions in cell and gene therapy applications, and growth of our storage services platform all point to continued validation of our class-defining bioproduction tools and services as highly preferred in our target markets. For the full year 2022, we gained over 1,300 new customers via our direct sales team and global network of distributors. Our engineering, quality and operations teams continued to focus on supply chain and other optimization initiatives for our freezers and thaw platform and we expect to continue to drive a mix shift to high margin, recurring revenue."

      Troy Wichterman, Chief Financial Officer, remarked, "We achieved full year 2022 positive adjusted EBITDA of $3.6 million and ended the year with $64.1 million in cash and short-term investments. As of today, Silicon Valley Bank is operational and fully honoring existing credit facilities. We currently have no additional need for capital."

      Operational Highlights

      New Customer Acquisition




      Platform/Solution

      Q4 2022

      FY2022

      Biopreservation Media

      15

      69

      Sexton Cell Processing

      5

      33

      SciSafe® Storage Services

      26

      99

      Thaw

      7

      35

      evo® Cold Chain

      12

      43

      Cryogenic Freezers

      13

      82

      ULT Freezers

      139

      461

      TOTAL

      217

      822

      • New distributor indirect customers totaled at least 500 in FY2022, bringing total new customers to over 1,300 for the year.
      • USA Master File cross references for our cell processing solutions were 27 in Q4 and 80 in FY 2022. Total global clinical applications with our cell processing solutions embedded are now estimated to be over 600, including 12 approved therapies, with 5 additional approvals possible in 2023. Sexton cell processing solutions are now embedded in 3 approved CGT medicines and in over 60 clinical trials.
      • evo cold chain management shipments of cell and gene therapies totaled 2,241 in Q4 and 7,201 in FY 2022, representing over 200% annual growth over 2021.

      Fourth Quarter 2022 Financial Results

      BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

      REVENUE

      • Total revenue for the fourth quarter of 2022 was $44.3 million, an increase of $7.0 million, or 19%, from $37.3 million for the fourth quarter of 2021. COVID-19 related revenue was approximately 5%, compared with approximately 15% in Q4 2021.

        • Cell Processing platform revenue was $20.2 million, up $5.3 million, or 36%, over the same period in 2021. Biopreservation growth was 35%.

        • Freezers and Thaw Systems platform revenue was $17.4 million, up $806,000, or 5%, over the same period in 2021. COVID-19 related revenue in 2022 was approximately 3% for this platform.

        • Storage and Storage Services platform revenue was $6.7 million, up $810,000, or 14%, over the same period in 2021. COVID-19 related revenue in 2022 was approximately 21% for this platform.
      • Total revenue for 2022 was $161.8 million, an increase of $42.6 million, or 36%, from $119.2 million for 2021. Organic revenue growth was 38%. COVID-19 related revenue was approximately 8%, compared with approximately 15% in 2021.

        • Cell Processing platform revenue was $68.5 million, up $23.5 million, or 52%, over 2021. Biopreservation media and organic cell processing growth were both 45%.

        • Freezers and Thaw Systems platform revenue was $66.8 million, up $10.1 million, or 18%, over 2021. Organic growth was 9%. COVID-19 related revenue in 2022 was approximately 4%.

        • Storage and Storage Services platform revenue was $26.5 million, up $8.9 million, or 51% over 2021; all growth was organic. COVID-19 related revenue in 2022 was approximately 39%.

      GROSS MARGIN

      • Gross margin (GAAP) for the fourth quarter of 2022 was 30% compared with 13% for the fourth quarter of 2021. Adjusted gross margin (non-GAAP) for the fourth quarter of 2022 was 32% compared with 17% for the fourth quarter of 2021.
      • Gross margin (GAAP) for 2022 was 30% compared with 27% for 2021. Adjusted gross margin (non-GAAP) for 2022 was 33% compared with 32% for 2021.
      • The increase in quarterly gross margin and adjusted gross margin was primarily due to decreased warranty expenses compared with 2021.

      OPERATING EXPENSE

      • Operating expense (GAAP) for the fourth quarter of 2022 was $93.5 million compared with $54.9 million for the fourth quarter of 2021. Adjusted operating expense (non-GAAP) for the fourth quarter of 2022 was $22.1 million compared with $19.2 million for the fourth quarter 2021.
      • Operating expense (GAAP) for 2022 was $307.3 million compared with $154.3 million for 2021. Adjusted operating expense (non-GAAP) for 2022 was $83.4 million compared with $59.6 million for 2021.
      • The increase in GAAP operating expense for the fourth quarter of 2022 was primarily due to a non-cash impairment charge of $40.5 million related to the acquired intangible assets of Global Cooling, Inc. (Stirling Ultracold). The increase in GAAP operating expense for 2022 was primarily due to non-cash impairment charges of $110.4 million related to the acquired intangible assets of Global Cooling, full period of ownership following the acquisition of Global Cooling on May 3, 2021, and the acquisition of Sexton Biotechnologies, Inc. on September 1, 2021, and personnel costs. Adjusted operating expenses (non-GAAP) increased due to the full period of ownership from the acquisition of Global Cooling and the acquisition of Sexton, Inc. In addition, operating expenses increased due to higher accounting costs related to becoming an Accelerated Filer, additional headcount to support our growth, and historical true-up of indirect tax expense.

      OPERATING LOSS

      • Operating loss (GAAP) for the fourth quarter of 2022 was $49.3 million compared with $17.6 million for the fourth quarter of 2021. Adjusted operating loss (non-GAAP) for the fourth quarter of 2022 was $8.2 million compared with $13.1 million for the fourth quarter of 2021.
      • Operating loss (GAAP) for 2022 was $145.5 million compared with $35.2 million for 2021. Adjusted operating loss (non-GAAP) for 2022 was $29.3 million compared with $21.5 million for 2021.

      NET LOSS

      • Net loss (GAAP) for the fourth quarter of 2022 was $49.2 million compared with $14.8 million for the fourth quarter of 2021. Adjusted net loss (non-GAAP) for the fourth quarter of 2022 was $8.2 million compared with $12.9 million for the fourth quarter of 2021.
      • Net loss (GAAP) for 2022 was $139.8 million compared with $8.9 million for 2021. Adjusted net loss (non-GAAP) for 2022 was $29.3 million compared with $15.4 million for 2021.

      EARNINGS/(LOSS) PER SHARE

      • Loss per share (GAAP) for the fourth quarter of 2022 was $1.15 compared with loss per share of $0.366 for the fourth quarter of 2021.
      • Loss per share (GAAP) for 2022 was $3.29 and included non-cash intangible impairment charges of $2.60 per share. This is compared with loss per share of $0.233 for 2021.

      ADJUSTED EBITDA

      • Adjusted EBITDA, a non-GAAP measure, for the fourth quarter of 2022 was $1.7 million compared with negative $5.9 million for the fourth quarter of 2021.
      •  Adjusted EBITDA, a non-GAAP measure, for the full year of 2022 was positive $3.6 million compared with $4.1 million for 2021.

      CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

      • Cash, cash equivalents, and marketable securities as of December 31, 2022, were $64.1 million.

      2023 Revenue Guidance

      Mike Rice, Chairman and CEO, further commented, "We fully expect to participate in the forecasted growth of the CGT industry over the next several years. Sustained catalysts that we expect to drive BioLife growth due to a significant increase in the number of manufactured doses include:

      • Approvals of new cell and gene therapies
      • Additional approvals of commercial CGT in new geographies
      • Additional approvals of CGT in new indications
      • Migration of commercial therapies to first or second-line treatment
      • An eventual transition to allogeneic therapies

      We remain confident that we will achieve our Q4 2024 run rate aspirational financial goals of $250 million in revenue, 50 points of adjusted gross margin and 30 points of adjusted EBITDA."

      BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business.

      Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID-19-related revenue, this range reflects year-over-year growth of 26% to 35%. Approximately 45% of 2023 total revenue is expected in the first half of the year and approximately 55% in the second half of the year, reflecting typical seasonality. Revenue guidance for 2023 does not include any COVID-19-related revenue.

      Expectations for 2023 total revenue include the following platform contributions:

      • Cell processing platform: $89.0 million to $93.0 million, an increase of 30% to 35% over 2022.
      • Freezers and Thaw Systems platform: $72.5 million to $79.0 million, an increase of 9% to 18% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 13% to 23%.
      • Storage and Storage Services platform: $26.5 million to $30.0 million, flat to an increase of 13% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 64% to 86%.

      Management expects gross margin and adjusted EBITDA expansion in 2023.

      Conference Call & Webcast

      Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

      To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 3739539. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

      About BioLife Solutions

      BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

      Cautions Regarding Forward Looking Statements

      Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company, the Company's ability to implement its business strategy and anticipated business and operations, the expected synergies between the Company and the companies and products that it has acquired, the potential utility of and market for the Company's products and services, including the adoption of the Company's products for new clinical candidates in connection with expected clinical trials, and the Company's ability to cross sell its products and services, guidance for financial results for 2023, 2024 and 2025, including regarding potential revenue growth and changes in product mix of total revenue and gross margin, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our acquisitions, market adoption of the Company's products, the ability of the Company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

      Non-GAAP Measures of Financial Performance:

      To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

      Media & Investor Relations

      At the Company

      Troy Wichterman 
      Chief Financial Officer 
      (425) 402-1400 
      [email protected]

      Investors

      LHA Investor Relations
      Jody Cain
      (310) 691-7100
      [email protected]

      BIoLife Solutions, Inc.

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited, amounts in thousands, except share and per share amounts)
















      Three Months Ended


      Year Ended



      December 31,


      December 31,

      (In thousands, except per share and share data)


      2022


      2021


      2022


      2021














      Product revenue


      $

      37,796


      $

      31,468


      $

      136,000


      $

      101,913

      Service revenue



      4,168



      3,400



      15,308



      9,817

      Rental revenue



      2,295



      2,436



      10,451



      7,426

      Total revenue



      44,259



      37,304



      161,759



      119,156

      Costs and operating expenses:













      Cost of product, rental, and service revenue
      (exclusive of Intangible asset amortization)



      30,287



      31,140



      107,937



      82,108

      Research and development



      4,164



      3,571



      14,798



      11,821

      Sales and marketing



      5,987



      4,778



      21,570



      14,006

      General and administrative



      12,575



      10,713



      47,670



      33,668

      Intangible asset amortization



      1,457



      2,863



      9,696



      8,202

      Acquisition costs



      -



      20



      18



      1,636

      Change in fair value of contingent consideration



      (1,405)



      1,790



      (4,754)



      2,875

      Intangible asset impairment charges



      40,464



      -



      110,364



      -

      Total operating expenses



      93,529



      54,875



      307,299



      154,316

      Operating loss



      (49,270)



      (17,571)



      (145,540)



      (35,160)














      Other income (expense), net













      Change in fair value of warrant liability



      -



      -



      -



      (121)

      Change in fair value of investments



      -



      -



      697



      -

      Interest expense, net



      (438)



      (118)



      (687)



      (485)

      Other expense



      432



      299



      703



      289

      Gain on acquisition of Sexton Biotechnologies, Inc.



      -



      -



      -



      6,451

      Total other (expense) income



      (6)



      181



      713



      6,134














      Loss before income tax benefit



      (49,276)



      (17,390)



      (144,827)



      (29,026)

      Income tax benefit



      86



      2,578



      5,022



      20,118

      Net loss


      $

      (49,190)


      $

      (14,812)


      $

      (139,805)


      $

      (8,908)














      Net loss attributable to common shareholders













      Basic and Diluted


      $

      (1.15)


      $

      (0.36)


      $

      (3.29)


      $

      (0.23)

      Diluted


      $

      (1.15)


      $

      (0.36)


      $

      (3.29)


      $

      (0.23)

      Weighted average shares used to compute loss
      per share attributable to common shareholders:













      Basic



      42,791,040



      41,675,256



      42,481,027



      38,503,944

      Diluted



      42,791,040



      41,675,256



      42,481,027



      38,503,944














      BIoLife Solutions, Inc.

      CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

      (Unaudited, amounts in thousands, except per share amounts)
















      Three Months Ended


      Year Ended



      December 31,


      December 31,

      (In thousands)


      2022


      2021


      2022


      2021














      NET LOSS


      $

      (49,190)


      $

      (14,812)


      $

      (139,805)


      $

      (8,908)

      Other comprehensive income/(loss)                 



      579



      (119)



      (397)



      (282)

      COMPREHENSIVE LOSS


      $

      (48,611)


      $

      (14,931)


      $

      (140,202)


      $

      (9,190)














      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

      (Unaudited, amounts in thousands)










      December 31,


      December 31,

      (In thousands)


      2022


      2021

      Cash, cash equivalents, and marketable securities                                    


      $

      64,065


      $

      69,870

      Working capital



      93,870



      83,388

      Current assets



      138,452



      126,088

      Current liabilities



      44,582



      42,700

      Total assets



      450,229



      554,285








      Long-term obligations



      41,459



      33,539

      Accumulated deficit



      (246,915)



      (107,109)

      Total shareholders' equity


      $

      364,188


      $

      478,046








      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

      (Unaudited, amounts in thousands)










      Year Ended



      December 31,

      (In thousands)


      2022


      2021

      Net cash used in operating activities


      $

      (8,489)


      $

      (4,593)

      Net cash used in investing activities



      (58,117)



      (13,192)

      Net cash provided by (used in) financing activities



      16,317



      (2,778)

      Effects of currency translation



      (108)



      (23)

      Net decrease in cash, cash equivalents and restricted stock                                   


      $

      (50,397)


      $

      (20,586)








      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

      (Unaudited, amounts in thousands)

















      Three Months Ended


      Year Ended




      December 31,


      December 31,


      (In thousands)


      2022


      2021


      2022


      2021


      GAAP GROSS PROFIT


      $

      13,329


      $

      4,675


      $

      48,815


      $

      32,491


      GAAP GROSS MARGIN



      30

      %


      13

      %


      30

      %


      27

      %















      ADJUSTMENTS TO GROSS PROFIT:                         














      Inventory step-up



      -



      -



      251



      1,130


      Intangible asset amortization



      733



      1,489



      5,007



      4,557


      ADJUSTED GROSS PROFIT


      $

      13,972


      $

      6,164


      $

      54,073


      $

      38,178


      ADJUSTED GROSS MARGIN



      32

      %


      17

      %


      33

      %


      32

      %















      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

      (Unaudited, amounts in thousands)








      Three Months Ended 


      Year Ended



      December 31,


      December 31,

      (In thousands)


      2022


      2021


      2022


      2021

      GAAP OPERATING EXPENSES


      $

      93,529


      $

      54,875


      $

      307,299


      $

      154,316
















      ADJUSTMENTS TO OPERATING EXPENSES:














      Cost of product, rental, and service revenue



      (30,287)



      (31,140)



      (107,937)



      (82,108)


      Acquisition costs



      -



      (20)



      (18)



      (1,636)


      Intangible asset amortization



      (1,457)



      (2,863)



      (9,696)



      (8,202)


      Loss on disposal of assets



      (595)



      170



      (683)



      145


      Change in fair value of contingent consideration             



      1,405



      (1,790)



      4,754



      (2,875)


      Intangible asset impairment charges



      (40,464)



      -



      (110,364)



      -


      ADJUSTED OPERATING EXPENSES


      $

      22,131


      $

      19,232


      $

      83,355


      $

      59,640
















      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

      (Unaudited, amounts in thousands)




      Three Months Ended


      Year Ended



      December 31,


      December 31,



      2022


      2021


      2022


      2021

      GAAP OPERATING LOSS


      $

      (49,270)


      $

      (17,571)


      $

      (145,540)


      $

      (35,160)














      ADJUSTMENTS TO OPERATING LOSS:













      Inventory step-up



      -



      -



      251



      1,130

      Acquisition costs



      -



      20



      18



      1,636

      Intangible asset amortization



      1,457



      2,863



      9,696



      8,202

      Loss on disposal of assets



      595



      (170)



      683



      (145)

      Change in fair value of contingent consideration



      (1,405)



      1,790



      (4,754)



      2,875

      Intangible asset impairment charges



      40,464



      -



      110,364



      -

      ADJUSTED OPERATING LOSS


      $

      (8,159)


      $

      (13,068)


      $

      (29,282)


      $

      (21,462)














      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

      (Unaudited, amounts in thousands)
















      Three Months Ended


      Year Ended



      December 31,


      December 31,

      (In thousands)


      2022


      2021


      2022


      2021

      GAAP NET LOSS


      $

      (49,190)


      $

      (14,812)


      $

      (139,805)


      $

      (8,908)














      ADJUSTMENTS TO NET LOSS:













      Inventory step-up



      -



      -



      251



      1,130

      Acquisition costs



      -



      20



      18



      1,636

      Intangible asset amortization



      1,457



      2,863



      9,696



      8,202

      Loss on disposal of assets



      595



      (170)



      683



      (145)

      Change in fair value of contingent consideration          



      (1,405)



      1,790



      (4,754)



      2,875

      Change in fair value of investments



      -



      -



      (697)



      -

      Change in fair value of warrant liability



      -



      -



      -



      (121)

      Income tax benefit



      (86)



      (2,578)



      (5,022)



      (20,118)

      Intangible asset impairment charges



      40,464



      -



      110,364



      -

      ADJUSTED NET LOSS


      $

      (8,165)


      $

      (12,887)


      $

      (29,266)


      $

      (15,449)














      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

      (Unaudited, amounts in thousands)
















      Three Months Ended


      Year Ended



      December 31,


      December 31,

      (In thousands)


      2022


      2021


      2022


      2021

      GAAP NET INCOME/(LOSS)


      $

      (49,190)


      $

      (14,812)


      $

      (139,805)


      $

      (8,908)














      ADJUSTMENTS:













      Interest expense/(income), net



      438



      118



      687



      485

      Income tax benefit



      (86)



      (2,578)



      (5,022)



      (20,118)

      Depreciation



      1,790



      1,790



      6,834



      4,801

      Intangible asset amortization



      1,457



      2,863



      9,696



      8,202

      EBITDA


      $

      (45,591)


      $

      (12,619)


      $

      (127,610)


      $

      (15,538)














      OTHER ADJUSTMENTS:













      Share-based compensation (non-cash)



      7,663



      5,082



      25,334



      13,973

      Inventory step-up



      -



      -



      251



      1,130

      Acquisition costs



      -



      20



      18



      1,636

      Loss on disposal of assets



      595



      (170)



      683



      (145)

      Change in fair value of contingent consideration          



      (1,405)



      1,790



      (4,754)



      2,875

      Change in fair value of investments



      -



      -



      (697)



      -

      Change in fair value of warrant liability



      -



      -



      -



      121

      Intangible asset impairment charges



      40,464



      -



      110,364



      -

      ADJUSTED EBITDA


      $

      1,726


      $

      (5,897)


      $

      3,589


      $

      4,052














      SOURCE BioLife Solutions, Inc.

      Modal title

      Also from this source

      BioLife Solutions Reports Second Quarter 2026 Financial Results

      BioLife Solutions Reports Second Quarter 2026 Financial Results

      BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the...

      BioLife Solutions Reports First Quarter 2026 Financial Results

      BioLife Solutions Reports First Quarter 2026 Financial Results

      BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.